Skip to content


    Exciting News for WebMD Members!

    We've been busy behind the scenes building new message boards for you. You'll have new and easier ways to find messages, connect with others, and share your stories.

    And, this will all be available on your smartphone or other mobile device!

    What Do You Need to Do?

    The message board you're used to will be closing in the coming weeks. While many of your boards will be making the move to our new home, your posts will not. Want to keep a discussion going? Save posts you want to continue (this includes your member profile story), so that you can re-post them in the new message boards.

    Keep an eye here and on your email inbox, we'll be back in touch soon to give you all the information you need!

    Yours in health,
    WebMD Message Boards Management

    Androgen deprivation therapy & insulin resistance
    BillH99 posted:
    Insulin-like growth factor pathway: A link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer? - Abstract
    Division of Hematology/Oncology, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.

    Androgen deprivation therapy (ADT) is standard of care for patients with metastatic hormone-sensitive prostate cancer (HSPC), yet through its induction of a hypogonadal state leads to metabolic perturbations, including insulin resistance (IR) and obesity. IR and obesity have been associated with an increased risk of progression to castrate-resistant prostate cancer (CRPC) and ultimately increased prostate cancer-specific mortality. On a molecular level, this association between obesity/IR and prostate cancer progression may be mediated by alterations in the insulin-like growth factor (IGF) axis, which has been shown to be up-regulated upon disease progression to CRPC. Targeting the IGF axis, either by anti-IGF therapy or via enhancement of peripheral insulin sensitivity, represents a viable therapeutic target in patients with prostate cancer. Using the development of IR and/or obesity may represent a clinically available biomarker that may predict those patients most likely to respond to such therapy, and warrants testing in future prospective clinical trials.
    Written by:
    Aggarwal RR, Ryan CJ, Chan JM. Are you the author?
    Reference: Urol Oncol. 2011 Jun 7. Epub ahead of print.
    doi: 10.1016/j.urolonc.2011.05.001
    [a>PubMed Abstract
    PMID: 21658978 Prostate Cancer Section
    Was this Helpful?
    1 of 2 found this helpful
    BobKy responded:
    Hi BillH99,


    Researchers have been looking at the IGF/PCa relationship for years;hopefully, they're getting closer to understanding why this happens and how to use it in treating PCa.


    Helpful Tips

    How to get the most out of your prostate cancer consultationExpert
    Here are a few tips to get the most out of your prostate cancer surgical or radiation oncology consultation: 1. Have extra copies of all ... More
    Was this Helpful?
    5 of 5 found this helpful

    Related Drug Reviews

    • Drug Name User Reviews

    Report Problems With Your Medications to the FDA

    FDAYou are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

    For more information, visit the Duke Health Prostate Cancer Center